Cybin has added to this growing IP portfolio with the granting of two more patents for its DMT program. The post Cybin Granted Two New Patents...
–New United States patent grants offer protection for deuterated analogs of DMT including composition of matter, medical use and synthesis – – Intellectual...
Cybin Inc. (NYSE AMERICAN:CYBN) (NEO:CYBN) (“Cybin” or the “Company”), a clinical-stage biopharmaceutical company committed to revolutionizing...
Cybin shareholders approve the acquisition of Small Pharma with 99.4% of the vote. The post Cybin Shareholders Approve Acquisition of Small Pharma appeared...
–Abstract entitled, “Structure-activity of 2C-X psychedelics to develop a novel 5-HT2A receptor full agonist with therapeutic potential” – –...
–Topline efficacy data expected in Q4 2023 – – Preparations are underway to scale the CYB003 program to a potential Phase 3 study in early 2024...
The two companies also shared next steps in their drug testing regimens. The post Atai, Cybin Give Positive Psychedelic Drug Study Updates appeared first...
Cybin moves its lead program forward as it completes enrollment of its Phase 2 study of major depressive disorder. The post Cybin Completes Phase 2 Enrollment...
Cybin Inc. (NYSE American:CYBN) (NEO:CYBN) (“Cybin” or the “Company”), a clinical-stage biopharmaceutical company committed to revolutionizing...
–Phase 2 topline efficacy data for CYB003 on track for Q4 2023, followed by U.S. Food and Drug Administration (“FDA”) submission of CYB003 Phase...